Judge To Keep J&J CEO Off Stand In Risperdal Case

Law360, Philadelphia (September 26, 2012, 8:45 PM EDT) -- A Pennsylvania state judge said Monday that he won't reconsider his order quashing testimony from Johnson & Johnson's CEO as part of litigation accusing a J&J subsidiary of marketing antipsychotic drug Risperdal for off-label use in children despite the risk of side effects.

Court of Common Pleas Judge Arnold New said he would not revisit his Sept. 20 order nixing testimony from Alex Gorsky, who served as head of Ortho-McNeill-Janssen Pharmaceuticals Inc. at the time the company was allegedly promoting Risperdal to physicians of children and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.